ClinicalTrials.gg
RecruitingNCT06997029Updated Oct 6, 2026

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase 1 interventional study of BMS-986500 and Palbociclib in Advanced Solid Tumor, Advanced Breast Cancer and Advanced Ovarian Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
234
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

02

Conditions studied

  • Advanced Solid Tumor
  • Advanced Breast Cancer
  • Advanced Ovarian Cancer

Browse trials for

Keywords

  • cancer
  • oncology
  • solid tumor
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 234 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥ 18 years of age.
  • Participants must have confirmed diagnosis of a locally advanced, unresectable, or solid tumor .
  • Participants must have a per (RECIST) v1.1
  • Participants must have a stable Performance Status of 0 or 1.
  • For Part 2A only, participants must have CCNE1-amplified ovarian cancer

Exclusion criteria

Exclusion Criteria:

  • Participants must not have an active .
  • Participants must not have impaired cardiac function or cardiac disease.
  • Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
  • Participants must not have Grade ≥ 2 peripheral neuropathy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (estimated)

Study arms

  • Experimental
    Part 1A Monotherapy Dose Escalation

    Drug: BMS-986500

  • Experimental
    Part 1B Combination Dose Escalation

    Drug: BMS-986500 · Drug: Palbociclib · Drug: Fulvestrant

  • Experimental
    Part 1C Monotherapy Pharmacodynamic (PD) Sub-study

    Drug: BMS-986500

  • Experimental
    Part 2A Monotherapy Dose Expansion

    Drug: BMS-986500

  • Experimental
    Part 2B Combination Dose Expansion

    Drug: BMS-986500 · Drug: Palbociclib · Drug: Fulvestrant

Interventions

  • DrugBMS-986500

    Specified dose of specified days

  • Specified dose on specified days

    Also known as: IBRANCE®, PD 0332991

  • Specified dose on specified days

    Also known as: FASLODEX®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Up to Day 28 From Last Dose

  2. Number of Participants With Adverse Events (AEs)

    Time frame: Up to Day 28 From Last Dose

  3. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to Day 28 From Last Dose

  4. Number of Participants With AEs Leading to Discontinuation

    Time frame: Up to Day 28 From Last Dose

  5. Number of Participants With TEAEs Leading to Death

    Time frame: Up to Day 28 From Last Dose

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of BMS-986500

    Time frame: Up to Approximately 2 Years

  2. Time of Maximum Observed Serum Concentration (Tmax) of BMS-986500

    Time frame: Up to Approximately 2 Years

  3. Area Under the Concentration-time Curve Within a Dosing Interval (AUC(TAU)) of BMS-986500

    Time frame: Up to Approximately 2 Years

07

Study locations

18 of 21 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
    Recruiting
    • Mehmet Akce, Site 0001 · Contact205-975-0832
  • Providence St. Jude Medical Center
    Fullerton, California 92835, United States
    Recruiting
    • Yung Lyou, Site 0003 · Contact714-446-5900
  • Marin Cancer Care
    Greenbrae, California 94904, United States
    Recruiting
    • Cyrus Mazidi, Site 0013 · Contact415-925-5000
  • Moores Cancer Center
    La Jolla, California 92093, United States
    Recruiting
    • Peter Vu, Site 0009 · Contact858-822-2463
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
    • Monica Mita, Site 0010 · Contact949-764-4060
  • Local Institution - 0008
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • Site 0008 · Contact
  • Local Institution - 0006
    Boston, Massachusetts 02215, United States
    Completed

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Faisal Fa'ak, Site 0004 · Contact
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Lionel Lewis, Site 0002 · Contact603-381-1953
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
    Recruiting
    • Christos Fountzilas, Site 0014 · Contact716-845-4720
  • Northwell Health-Cancer Institute
    New Hyde Park, New York 11042, United States
    Recruiting
    • Geraldine O'Sullivan Coyne, Site 0016 · Contact
  • Local Institution - 0011
    New York, New York 10016, United States
    Not yet recruiting
    • Site 0011 · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Ezra Rosen, Site 0012 · Contact000-000-0000
  • START Dallas Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
    • Henry Xiong, Site 0018 · Contact682-350-3010
  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • David Sommerhalder, Site 0007 · Contact210-580-9500
  • Odense Universitetshospital
    Odense, Region Syddanmark 5000, Denmark
    Recruiting
    • Annette Kodahl, Site 0024 · Contact004566113333
  • Copenhagen University Hospital
    Copenhagen, 2100, Denmark
    Recruiting
    • Martin Højgaard, Site 0025 · Contact4535456861
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Chikako Funasaka, Site 0021 · Contact81471331111
  • Kansai Medical University Hospital
    Hirakata, Osaka 573-1191, Japan
    Recruiting
    • Toshio Shimizu, Site 0020 · Contact+81728040101
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Takafumi Koyama, Site 0022 · Contact81335422511
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
    Recruiting
    • Shigehisa Kitano, Site 0023 · Contact0335200111
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 40 months is close to that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 14, 2028
CompletionEst.
Dec 14, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Local Institution - 0006 · Boston, United States
Show 1 removed
  • Dana-Farber Cancer Institute · Boston, United States
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Local Institution - 0006 · Boston, United States
    Show 1 removed
    • Dana-Farber Cancer Institute · Boston, United States
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06997029
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Aug 1, 2025
Primary completion
Dec 14, 2028 (estimated)
Completion
Dec 14, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion